Search Results Search Sort by RelevanceMost Recent Policy Forum Jul 2016 Protecting Pharmaceutical Patents and Test Data: How the Trans-Pacific Partnership Agreement Could Affect Access to Medicines in the US and Abroad Jing Luo, MD and Aaron S. Kesselheim, MD, JD, MPH The Trans-Pacific Partnership Agreement could affect low-income patients’ access to medicines in signatory countries by reducing generic competition. AMA J Ethics. 2016;18(7):727-735. doi: 10.1001/journalofethics.2016.18.7.pfor1-1607. Policy Forum Aug 2019 Should a Law Governing the Pharmaceutical Market Be Ethically Examined Based on Its Intent or Its Practical Applications? Jordan M. Warchol, MD, MPH In 1984, Hatch-Waxman tried to balance drug innovation against availability; it was tested in the US Supreme Court in 2013. AMA J Ethics. 2019;21(8):E661-667. doi: 10.1001/amajethics.2019.661. Policy Forum Aug 2019 Why Are Biosimilars Not Living up to Their Promise in the US? Mike Z. Zhai, Ameet Sarpatwari, JD, PhD, and Aaron S. Kesselheim, MD, JD, MPH Overall utilization of the few biosimilars currently available to patients has been limited. AMA J Ethics. 2019;21(8):E668-678. doi: 10.1001/amajethics.2019.668. Policy Forum Mar 2020 What Should Health Care Organizations Do to Reduce Billing Fraud and Abuse? Katherine Drabiak, JD and Jay Wolfson, DrPH, JD Upcoding and misrepresenting clinical information constitute fraud, cost a lot, and can result in patient harm and unnecessary procedures and prescriptions. AMA J Ethics. 2020;22(3):E221-231. doi: 10.1001/amajethics.2020.221. Policy Forum Jun 2006 Reputation, Gatekeeping, and the Politics of Post-Marketing Drug Regulation Daniel Carpenter, PhD Virtual Mentor. 2006;8(6):403-406. doi: 10.1001/virtualmentor.2006.8.6.pfor1-0606. Health Law Jun 2005 A Physician's Role in Informing Family Members of Genetic Risk Faith Lagay, PhD Virtual Mentor. 2005;7(6):435-437. doi: 10.1001/virtualmentor.2005.7.6.hlaw1-0506. Health Law Nov 2007 Referral Schemes at Imaging Centers Abigail Van Kempen Virtual Mentor. 2007;9(11):762-764. doi: 10.1001/virtualmentor.2007.9.11.hlaw1-0711. Health Law Oct 2005 HIV and Health Law: Striking the Balance between Legal Mandates and Medical Ethics Laura Lin, MBA, JD and Bryan A. Liang, MD, PhD, JD Virtual Mentor. 2005;7(10):687-692. doi: 10.1001/virtualmentor.2005.7.10.hlaw1-0510. Health Law Jul 2003 Is it Legal for a Physician to Receive Payment for Prescribing a Drug? Kristin A. Sorenson Virtual Mentor. 2003;5(7):260-262. doi: 10.1001/virtualmentor.2003.5.7.hlaw1-0307. Health Law Oct 2003 In Defense of Exceptions to Confidentiality Dudley Stewart, MD Virtual Mentor. 2003;5(10):445-448. doi: 10.1001/virtualmentor.2003.5.10.hlaw1-0310. Pagination Current page 1 Page 2 Next page Next › Last page Last »
Policy Forum Jul 2016 Protecting Pharmaceutical Patents and Test Data: How the Trans-Pacific Partnership Agreement Could Affect Access to Medicines in the US and Abroad Jing Luo, MD and Aaron S. Kesselheim, MD, JD, MPH The Trans-Pacific Partnership Agreement could affect low-income patients’ access to medicines in signatory countries by reducing generic competition. AMA J Ethics. 2016;18(7):727-735. doi: 10.1001/journalofethics.2016.18.7.pfor1-1607.
Policy Forum Aug 2019 Should a Law Governing the Pharmaceutical Market Be Ethically Examined Based on Its Intent or Its Practical Applications? Jordan M. Warchol, MD, MPH In 1984, Hatch-Waxman tried to balance drug innovation against availability; it was tested in the US Supreme Court in 2013. AMA J Ethics. 2019;21(8):E661-667. doi: 10.1001/amajethics.2019.661.
Policy Forum Aug 2019 Why Are Biosimilars Not Living up to Their Promise in the US? Mike Z. Zhai, Ameet Sarpatwari, JD, PhD, and Aaron S. Kesselheim, MD, JD, MPH Overall utilization of the few biosimilars currently available to patients has been limited. AMA J Ethics. 2019;21(8):E668-678. doi: 10.1001/amajethics.2019.668.
Policy Forum Mar 2020 What Should Health Care Organizations Do to Reduce Billing Fraud and Abuse? Katherine Drabiak, JD and Jay Wolfson, DrPH, JD Upcoding and misrepresenting clinical information constitute fraud, cost a lot, and can result in patient harm and unnecessary procedures and prescriptions. AMA J Ethics. 2020;22(3):E221-231. doi: 10.1001/amajethics.2020.221.
Policy Forum Jun 2006 Reputation, Gatekeeping, and the Politics of Post-Marketing Drug Regulation Daniel Carpenter, PhD Virtual Mentor. 2006;8(6):403-406. doi: 10.1001/virtualmentor.2006.8.6.pfor1-0606.
Health Law Jun 2005 A Physician's Role in Informing Family Members of Genetic Risk Faith Lagay, PhD Virtual Mentor. 2005;7(6):435-437. doi: 10.1001/virtualmentor.2005.7.6.hlaw1-0506.
Health Law Nov 2007 Referral Schemes at Imaging Centers Abigail Van Kempen Virtual Mentor. 2007;9(11):762-764. doi: 10.1001/virtualmentor.2007.9.11.hlaw1-0711.
Health Law Oct 2005 HIV and Health Law: Striking the Balance between Legal Mandates and Medical Ethics Laura Lin, MBA, JD and Bryan A. Liang, MD, PhD, JD Virtual Mentor. 2005;7(10):687-692. doi: 10.1001/virtualmentor.2005.7.10.hlaw1-0510.
Health Law Jul 2003 Is it Legal for a Physician to Receive Payment for Prescribing a Drug? Kristin A. Sorenson Virtual Mentor. 2003;5(7):260-262. doi: 10.1001/virtualmentor.2003.5.7.hlaw1-0307.
Health Law Oct 2003 In Defense of Exceptions to Confidentiality Dudley Stewart, MD Virtual Mentor. 2003;5(10):445-448. doi: 10.1001/virtualmentor.2003.5.10.hlaw1-0310.